Live Stock Price
Live Stock Price
COVID-19: COVA clinical program
The COVA study aims at evaluating therapeutic efficacy and safety of Ruvembri™ as a treatment to prevent further respiratory deterioration in patients who experience severe respiratory distress due to COVID-19. The Coronavirus SARS-CoV-2 can cause Acute Respiratory Distress Syndrome (ARDS) by disrupting the renin angiotensin system (RAS), which has a key role in regulating…
Details
2020
Posters & Publications 2020 SARA program: the use of BIO101, a MAS receptor agonist, for the treatment of sarcopenia. Industry sponsored session, annual digital meeting of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD). Tourette et al. SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study. Dioh et al.…
DetailsSEC Filings
SEC Filings Filing Date Form Description April 25, 2024 6-K On April 24, 2024, Biophytis S.A. issued a press release announcing the transfer of ADSs to OTC market. April 18, 2024 6-K On April 18, 2024, Biophytis S.A. issued a press release announcing the formation of a new Scientific Advisory Board for its phase 2…
DetailsAMF Regulated Information
Regulated Information In French: RAPPORT FINANCIER ANNUEL 2023 INCLUANT LE RAPPORT DE GESTION – EXERCICE CLOS LE 31 DECEMBRE 2023 In French: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2024 In French: Information mensuelle relative au nombre total des droits de vote et…
Details
2014
Posters & Publications 2014 The SARCOB program: a french consortium for developing drug candidate and nutraceutical targeting sarcopenic obesity. Dioh et al. Poster presentation at the 5th International Conference on Frailty & Sarcopenia Research (ICFSR), March 12-14, 2014, Barcelona, Spain. Abstract published in The Journal of Frailty & Aging, 3(1), 72-73, Abstract P186.
Details
2015
Posters & Publications 2015 BIO101, a drug candidate targeting sarcopenic obesity through MAS receptor activation. Raynal et al. Poster presentation at the 8th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 4-6, 2015, Paris, France. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 6(4), 429. Abstract 1-76.
Details
2016
Posters & Publications 2016 BIO101, a drug candidate targeting Mas Receptor for the treatment of age-related muscle degeneration. From molecular target identification to clinical development. Dilda et al. Poster presentation at the 9th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 10-11, 2016, Berlin, Germany. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 7(5), 655. Abstract 4-01. A…
Details
2017
Posters & Publications 2017 BIO103, a drug candidate for the treatment of muscle wasting disorders. Serova et al. Oral and poster presentations at the 10th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1067-1068. Abstract 8-09. SARA clinical program for evaluating safety and…
Details
2018
Posters & Publications 2018 BIO101 accelerates differentiation and enhances mitochondrial function in skeletal muscle cells. Serova et al. Oral presentation at the 11th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 7-9, 2018, Maastricht, Netherlands. Abstract published in Journal of Cachexia, Sarcopenia and Muscle 2018; 9; 1170. Abstract 4-11. Transitioning from SARA-OBS, an observational study to SARA-INT, a double-blind,…
Details